We are currently enrolling for the following studies:
Prophesys (MV21542)
Sponsor: Roche
Prospective observational study on predictors of early on-treatment response and sustained virological response in a cohort of treatment naive HCV-infected patients treated with pegylated interferons
One Group
Entecavir (AI463109)
Sponsor: Bristol-Myers Squibb
Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection
Group 1: Nucleoside/tide monotherapy with ETV
Group 2: Nucleoside/tide monotherapy with another standard of care HBV nucleoside/tide anologue
Truvada (GS-US-203-0107)
Sponsor: Gilead
A Phase 2, Open Label Randomized Study to Evaluate the Efficacy and Safety of the Combination Product, Emtricitabine/Tenofovir Disoproxil Fumarate in the Presence or Absence of Hepatitis B Immunoglobulin (HBIG) in Preventing Recurrence of Chronic Hepatitis B(CHB) Post-Orthotopic Liver Transplant (OLT)
Group 1: Truvada in combination with HBIG therapy
Group 2: Truvada
REALM (AI4603080)
Sponsor: Bristol-Myers Squibb
Randomized, Observational Study to Assess Long-term Outcomes Associated with Nucleoside/Nucleotide Monotherapy for Patients with Chronic HBV Infection: The REALM Study.
1:1 ratio
Group 1: ETV treatment
Group 2: Standard of care nucleoside/tide analogue
Rifaximin (RFHE3002)
Sponsor: Salix
A Multicenter Open-Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects with a History of Hepatic Encephalopathy
One group
Maribavir (1263-301)
Sponsor: ViroPharma
A Randomized, Double-blind study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants
1:1 ratio
Group 1: Maribivir
Group 2: Oral Ganciclovir
